HELP
Helus Pharma Inc.

7,575
Mkt Cap
$426.81M
Volume
5.37M
52W High
$9.83
52W Low
$4.81
PE Ratio
-1.89
HELP Fundamentals
Price
$5.47
Prev Close
$8.53
Open
$6.41
50D MA
$7.31
Beta
0.85
Avg. Volume
639,409.13
EPS (Annual)
-$4.02
P/B
1.55
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints
Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pressure on the stock.read more...
Benzinga·60m ago
News Placeholder
More News
News Placeholder
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion PR Newswire NEW YORK, March 5, 2026 GAD...
PR Newswire·2h ago
News Placeholder
FY2026 Earnings Forecast for Cybin Issued By HC Wainwright
Cybin Inc. (NASDAQ:HELP - Free Report) - Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Cybin in a research note issued to investors on Monday, March 2nd...
MarketBeat·2h ago
News Placeholder
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism
In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six weeks.
Stocktwits·3h ago
News Placeholder
Cybin (NASDAQ:HELP) Price Target Raised to $95.00 at HC Wainwright
HC Wainwright boosted their price target on Cybin from $55.00 to $95.00 and gave the company a "buy" rating in a report on Monday...
MarketBeat·3d ago
News Placeholder
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments PR Newswire VANCOUVER, BC, Feb. 27...
PR Newswire·6d ago
News Placeholder
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders PR Newswire VANCOUVER, BC, Feb. 26, 2026...
PR Newswire·7d ago
News Placeholder
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity PR Newswire NEW YORK, Feb. 24, 2026...
PR Newswire·9d ago
News Placeholder
HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’
The study showed statistically significant and clinically meaningful reductions in depressive symptoms at two weeks in participants treated with SPL026 compared with placebo, the company said.
Stocktwits·16d ago
News Placeholder
Cybin (NASDAQ:HELP) Announces Earnings Results
Cybin (NASDAQ:HELP - Get Free Report) posted its earnings results on Friday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by...
MarketBeat·20d ago
<
1
2
...
>

Latest HELP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.